Oseltamivir, 75 mg once (Osel qd) or twice (Osel bid) daily, v placebo for preventing influenzaâ€
| Outcomes at 6 wk | Comparison | Event rates | RRR (95% CI) | NNT (CI) |
|---|---|---|---|---|
| Laboratory confirmed influenza-like illness | Osel qd v placebo | 1.2% v 4.8% | 76% (46 to 91) | 27 (17 to 59) |
| Osel bid v placebo | 1.3% v 4.8% | 72% (40 to 89) | 29 (17 to 69) | |
| Combined groups v placebo | 1.3% v 4.8% | 74% (53 to 88) | 28 (17 to 55) |
| RRI (CI) | NNH (CI) | |||
|---|---|---|---|---|
| †Abbreviations defined in glossary; NNT and CI calculated from data in article; RRI and NNH calculated from data supplied by author. | ||||
| Nausea | Osel qd v placebo | 12.1% v 7.1% | 70% (16 to 150) | 20 (12 to 70) |
| Osel bid v placebo | 14.6% v 7.1% | 105% (42 to 198) | 13 (9 to 27) | |
| Vomiting | Osel qd v placebo | 2.5% v 0.8% | 224% (12 to 840) | 58 (28 to 479) |
| Osel bid v placebo | 2.7% v 0.8% | 249% (22 to 904) | 52 (26 to 267) | |